or Try an Advanced Search...

    Treprostinil Stocks List

    Symbol Grade Name % Change
    ASND D Ascendis Pharma A/S -6.23
    LQDA D Liquidia Technologies, Inc. -3.50
    UTHR B United Therapeutics Corporation 1.31
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Hypertension Pulmonary Arterial Hypertension Biotechnology Life Sciences Alcohol Biopharmaceutical Blastoma Brain Cancer Breakthrough Therapy Bupivacaine Chemical Compounds Chronic And Life Threatening Conditions Clinical Trial Diabetes Disease Drug Therapies Growth Hormone Growth Hormone Deficiency Growth Hormone Therapy Hepatitis C

    Related ETFs - A few ETFs which own one or more of the above listed Treprostinil stocks.

    Symbol Grade Name Weight
    MEDI D Harbor Health Care ETF 16.82
    PJP A PowerShares Dynamic Pharmaceuticals 4.4
    BBP B BioShares Biotechnology Products Fund 4.24
    SYNB B Putnam BioRevolution ETF 3.93
    FTXH C First Trust Nasdaq Pharmaceuticals ETF 3.88
    View all Treprostinil ETFs...
    Compare ETFs
    Compare BBP to FTXH Compare PJP to BBP Compare PJP to FTXH

        Treprostinil Stocks Recent News

        Date Stock Title
        May 14 ASND UPDATE 1-FDA extends review of Ascendis Pharma's hormone disorder therapy
        May 14 ASND Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism
        May 14 LQDA Liquidia Corporation (LQDA) Q1 2024 Earnings Call Transcript
        May 14 LQDA Down -11.26% in 4 Weeks, Here's Why You Should You Buy the Dip in Liquidia Technologies (LQDA)
        May 14 LQDA Liquidia GAAP EPS of -$0.54 misses by $0.24, revenue of $3M misses by $1.39M
        May 13 LQDA Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update
        May 13 LQDA Liquidia  Q1 2024 Earnings Preview
        May 13 ASND Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial
        May 10 UTHR Insmed (INSM) Beats on Q1 Earnings, Posts Upbeat Pipeline Updates
        May 10 UTHR Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates
        May 10 LQDA Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD
        May 9 UTHR CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss
        May 9 ASND Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024
        May 8 UTHR Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues
        May 8 ASND An Update On Ascendis Pharma's Path To Profitability
        Related Industries: Biotechnology
        Related Stock Lists: Hypertension Pulmonary Arterial Hypertension Biotechnology Life Sciences Alcohol Biopharmaceutical Blastoma Brain Cancer Breakthrough Therapy Bupivacaine Chemical Compounds Chronic And Life Threatening Conditions Clinical Trial Diabetes Disease Drug Therapies Growth Hormone Growth Hormone Deficiency Growth Hormone Therapy Hepatitis C
        Treprostinil

        Treprostinil (marketed under the trade names Remodulin for infusion, Orenitram for oral, and Tyvaso for inhalation) is a vasodilator that is used for the treatment of pulmonary arterial hypertension. Treprostinil is a synthetic analog of prostacyclin (PGI2).
        The inhaled form of treprostinil was approved by the FDA in July 2009 and is marketed as the trade name Tyvaso.

        More about Treprostinil
        Browse All Tags